Jazayeri 2017.

Study name	Effect of hesperidin supplementation on depressive symptoms, serum levels of BDNF and cortisol in patients after myocardial infarction
Methods	RCT design: 2‐arm parallel‐group trial Total N randomised: 70 Length of follow‐up: no follow‐up Analysis: not specified
Participants	Location: Iran Number of study centres and setting: not specified, affiliated with Iran University of Medical Sciences, Tehran CAD criteria: myocardial infarction in past 6 weeks Depression criteria: BDI score of 10 or higher Other entry criteria: willingness to co‐operate and signed informed consent, no use of supplements during the last 3 months (including omega‐3, Q10, antioxidants, and vitamins), absence of any allergies (gastrointestinal and skin) to any type of antioxidant supplements and vitamins, age 30 to 70 years, do not use more than 1 blood orange or more than 2 other citrus fruits a day, body mass index between 25 to 40 Exclusion criteria: major psychiatric disorder history, treatment of depression within past 12 months, consumes more than 500 mL per day of flavonoid‐rich beverages include tea, coffee, or citrus juice, major cognitive disorders or impaired cognitive function, lack of follow‐up after discharge, tobacco smoking, uncontrolled metabolic disease, pregnancy and lactation, use of heparin or warfarin, uncontrolled chronic diseases (hepatic failure, renal failure, diabetes, etc.), digestive disorders, compliance below 80%
Interventions	Intervention 1: hesperidin capsules 200 mg/d Control: placebo containing starch Duration of treatment: 3 months
Outcomes	Primary: depression measured by the BDI Secondary: serum levels of BDNF and cortisol
Starting date	5 May 2017
Contact information	Dr Shima Jazayeri Vice chancellor for research, Iran University of Medical Sciences, Besides Milad Tower, Hemmat, Tehran, Iran (Islamic Republic of) T: +98 21 8670 4805 E: Jazayeri.sh@iums.ac.ir; sh_jaz@yahoo.com
Notes